{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:12Z","timestamp":1792790472405,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jad.2023.11.076","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:06:03Z","timestamp":1700496363000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database"],"prefix":"10.1016","volume":"347","author":[{"given":"Haohao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhe","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jad.2023.11.076_bb0005","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS)[J]","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2023.11.076_bb0010","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s40265-019-01189-8","article-title":"Dopamine receptor partial agonists for the treatment of bipolar disorder[J]","volume":"79","author":"Azorin","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2023.11.076_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2023.11.076_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.jad.2023.11.076_bb0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41593-022-01062-0","article-title":"A D2 to D1 shift in dopaminergic inputs to midbrain 5-HT neurons causes anorexia in mice[J]","volume":"25","author":"Cai","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.jad.2023.11.076_bb0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S109285291900083X","article-title":"The role of dopamine D3 receptors in the mechanism of action of cariprazine[J]","volume":"25","author":"Calabrese","year":"2020","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.jad.2023.11.076_bb0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1906193","article-title":"Bipolar disorder[J]","volume":"383","author":"Carvalho","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.11.076_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12325-013-0004-9","article-title":"Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy[J]","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.jad.2023.11.076_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.24869\/psyd.2020.36","article-title":"Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials[J]","volume":"32","author":"Cooper","year":"2020","journal-title":"Psychiatr. Danub."},{"issue":"3","key":"10.1016\/j.jad.2023.11.076_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"issue":"1","key":"10.1016\/j.jad.2023.11.076_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial[J]","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"issue":"3","key":"10.1016\/j.jad.2023.11.076_bb0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression[J]","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.11.076_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA adverse event reporting system (FAERS) and international safety efforts: a systematic review from the research on adverse drug events and reports (RADAR) project[J]","volume":"95","author":"Edwards","year":"2013","journal-title":"J. Bone Joint Surg. Am."},{"issue":"6","key":"10.1016\/j.jad.2023.11.076_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2023.11.076_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.06.003","article-title":"Cholinergic nervous system and glaucoma: from basic science to clinical applications[J]","volume":"72","author":"Faiq","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"issue":"7","key":"10.1016\/j.jad.2023.11.076_bb0080","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.18240\/ijo.2023.07.05","article-title":"Effects of endogenous dopamine induced by low concentration atropine eye drops on choroidal neovascularization in high myopia mice[J]","volume":"16","author":"Ji","year":"2023","journal-title":"Int. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.jad.2023.11.076_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial[J]","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.076_bb0090","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40263-016-0382-z","article-title":"Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials[J]","volume":"30","author":"Lao","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2023.11.076_bb0095","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety[J]","volume":"38","author":"Laszlovszky","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.jad.2023.11.076_bb0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview[J]","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2023.11.076_bb0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2023.11.076_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data[J]","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.11.076_bb0115","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/s41467-019-10219-8","article-title":"Cholinergic neural activity directs retinal layer-specific angiogenesis and blood retinal barrier formation[J]","volume":"10","author":"Weiner","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723014453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723014453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:11:39Z","timestamp":1759032699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723014453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":23,"alternative-id":["S0165032723014453"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.076","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}